Research programe: cancer vaccines - Flashpoint therapeutics
Latest Information Update: 31 Mar 2025
At a glance
- Originator Flashpoint Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 12 Mar 2025 Early research in Cancer in USA (unspecified route) (Flashpoint Therapeutics pipeline, March 2025)